Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 6/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | CETP | P11597 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GMNN | O75496 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.40 |
| ▸ | CCR6 | P51684 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | UBE2N | P61088 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283559 | 1.00 | SPHK2 (0.40) | SPHK2SPHK1MEN1KMT2ALMNA | |
| SCHEMBL4285842 | 1.00 | SPHK2 (0.40) | SPHK2SPHK1MEN1KMT2ALMNA | |
| SCHEMBL4283555 | 1.00 | SPHK2 (0.40) | SPHK2SPHK1MEN1KMT2ALMNA | |
| SCHEMBL4284691 | 1.00 | SPHK2 (0.40) | SPHK2SPHK1MEN1KMT2ALMNA | |
| SCHEMBL4284696 | 1.00 | SPHK2 (0.40) | SPHK2SPHK1MEN1KMT2ALMNA | |
| SCHEMBL4284074 | 0.98 | SPHK2 (0.37) | SPHK2SPHK1MEN1KMT2ALMNA | |
| SCHEMBL4284078 | 0.98 | SPHK2 (0.37) | SPHK2SPHK1MEN1KMT2ALMNA | |
| SCHEMBL4281835 | 0.90 | — | — | |
| SCHEMBL4281838 | 0.90 | — | — | |
| SCHEMBL18134583 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0448740-B1 | A perfume composition | KAO CORP (JP) | 1995-10-18 | — | — | EP | claimed |
| US-8765809-B2 | Ester derivative and use thereof | AJINOMOTO CO., INC. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20130053441-A1 | NOVEL ESTER DERIVATIVE AND USE THEREOF | AJINOMOTO CO., INC. (JP) | 2013-02-28 | — | — | US | disclosed |
| US-8372802-B2 | Fluorinated macrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372802-B2 | Fluorinated macrocyclic compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8212068-B2 | Ester derivative and use thereof | AJINOMOTO CO., INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090238794-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090238794-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090170942-A1 | ESTER DERIVATIVE AND USE THEREOF | AJINOMOTO CO. INC (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-0448740-B1 | A perfume composition | KAO CORP (JP) | 1995-10-18 | — | — | EP | disclosed |
| US-5116813-A | Methyl-Branched Aliphatic Aldehyde or Alcohol | KAO CORPORATION (JP) | 1992-05-26 | — | — | US | disclosed |
| EP-0448740-A1 | A perfume composition | KAO CORPORATION (JP) | 1991-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053441-A1 | NOVEL ESTER DERIVATIVE AND USE THEREOF | MEP1A, CES2, MEP1B | SPHK2 2685/4885SPHK1 3038/4885MEN1 85/4885 |
| US-20090170942-A1 | ESTER DERIVATIVE AND USE THEREOF | MEP1A, CES2, F8 | SPHK2 3396/4885SPHK1 3546/4885MEN1 29/4885 |
| US-20090238794-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | CTSC, SPINT2, CTSV | SPHK2 2287/4885SPHK1 1522/4885MEN1 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.